# STIC Search Report
## Biotech-Chem Library

STIC Database Tracking Number: 148531

| TO: | From: |
|---|---|
| Abdel Mohamed<br>Location: rem/3b79/3c70<br>Art Unit: 1653<br>Monday, March 28, 2005<br><br>Case Serial Number: 10/036918 | Alex Waclawiw<br>Location: Biotech-Chem Library<br>CM1-6A02<br>Phone: 308-4491<br><br>Alexandra.waclawiw@uspto.gov |

## Search Notes

CRFF

Access DB# 148581

# SEARCH REQUEST FORM

## Scientific and Technical Information Center

Requester's Full Name: ABDEL MOHAMED Examiner #: 66323 Date: 03/22/05
Art Unit: 1653 Phone Number ~~30~~ 272-0955 Serial Number: 10/036,918
Mail Box and Bldg/Room Location: REM3 B79 Results Format Preferred (circle): PAPER DISK E-MAIL
REM3 C70

If more than one search is submitted, please prioritize searches in order of need. MEJ

**********

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: SP

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

*For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search SEQ ID NO: 4

AA - 8

Thanks
Abdel

MEJ



**********

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: 3-28
Date Completed: 3-28
Searcher Prep & Review Time: 15
Clerical Prep Time: _____
Online Time 25

Point of Contact:
Alexandra Waclawiw
Technical Info. Specialist.
CM1 6A02 Tel: 308-4491

Type of Search

NA Sequence (#) _____
AA Sequence (#) 1
Structure (#) _____
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN ✓
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) Compugen

PTO-1590 (8-01)

```
=> d his

     (FILE 'HOME' ENTERED AT 13:47:39 ON 28 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 13:47:45 ON 28 MAR 2005
L1             0 S GPGRPYGL/SQSP
L2           714 S .P.RPY.L/SQSP
L3            44 S L2 AND PIPERID?
                 E PIPERIDIN/CN
                 E PIPERIDINE/CN
L4             1 S E3
L5       2127679 S NC5/ES
L6            45 S L5 AND L2
L7             7 S L6 AND SQL=8

     FILE 'HCAPLUS' ENTERED AT 13:50:39 ON 28 MAR 2005
L8             2 S L7
```

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 13:51:18 ON 28 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 MAR 2005  HIGHEST RN 847353-93-9
DICTIONARY FILE UPDATES:  27 MAR 2005  HIGHEST RN 847353-93-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que l7
L2          714 SEA FILE=REGISTRY ABB=ON  PLU=ON  .P.RPY.L/SQSP
L5      2127679 SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ES
L6           45 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND L2
L7            7 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND SQL=8


=> d sqide3 l7 1-7

L7   ANSWER 1 OF 7  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   694452-76-1  REGISTRY
CN   L-Leucine, (2S)-2-(4-piperidinyl)-N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-
     tetraazacyclododec-1-yl]acetyl]glycyl-L-prolyl-(2S)-2-[1-
     (aminoiminomethyl)-4-piperidinyl]glycyl-L-arginyl-L-prolyl-L-tyrosyl-3-
     methyl-L-valyl- (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  8
NTE  modified (modifications unspecified)

SEQ3      1 Gly-Pro-Gly-Arg-Pro-Tyr-Val-Leu
            === === === === === === === ===
HITS AT:    1-8


**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
```

MF C68 H111 N19 O17
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Journal
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
RN 579449-02-8 REGISTRY
CN L-Leucine, (2S)-N-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-2-[1-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-4-piperidinyl]glycyl-L-prolyl-(2S)-2-[1-(aminoiminomethyl)-4-piperidinyl]glycyl-L-arginyl-L-prolyl-L-tyrosyl-3-methyl-L-valyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 8
NTE modified (modifications unspecified)

SEQ3 1 Gly-Pro-Gly-Arg-Pro-Tyr-Val-Leu
=== === === === === === === ===
HITS AT: 1-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF C94 H107 N17 O20 S2
CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
RN 579449-01-7 REGISTRY
CN L-Leucine, (2S)-2-[1-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-4-piperidinyl]glycyl-L-prolyl-(2S)-2-[1-(aminoiminomethyl)-4-piperidinyl]glycyl-L-arginyl-L-prolyl-L-tyrosyl-3-methyl-L-valyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 8
NTE modified (modifications unspecified)

SEQ3 1 Gly-Pro-Gly-Arg-Pro-Tyr-Val-Leu
=== === === === === === === ===
HITS AT: 1-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

MF C73 H96 N16 O15 S
CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

PAGE 1-A



PAGE 2-A



PAGE 3-A



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
RN 579449-00-6 REGISTRY
CN L-Leucine, (2S)-N-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-2-(4-piperidinyl)glycyl-L-prolyl-(2S)-2-[1-(aminoiminomethyl)-4-piperidinyl]glycyl-L-arginyl-L-prolyl-L-tyrosyl-3-methyl-L-valyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 8
NTE modified (modifications unspecified)

SEQ3 1 Gly-Pro-Gly-Arg-Pro-Tyr-Val-Leu
=== === === === === === === ===
HITS AT: 1-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF C73 H96 N16 O15 S
CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

PAGE 1-A



PAGE 2-A



PAGE 3-A



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
RN 579448-99-0 REGISTRY
CN 6-13-Neurotensin (cattle), 6-[N2,N6-bis[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-D-lysine]-8-[(2S)-2-[1-(aminoiminomethyl)-4-piperidinyl]glycine]- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE
SQL 8
NTE modified (modifications unspecified)

| type | location | | description |
|---|---|---|---|
| stereo | Lys-1 | - | D |

SEQ3 1 Lys-Pro-Gly-Arg-Pro-Tyr-Ile-Leu
=== === === === === === === ===
HITS AT: 1-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF C93 H107 N17 O20 S2
CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
RN 579448-98-9 REGISTRY
CN 6-13-Neurotensin (cattle), 6-[N6-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-D-lysine]-8-[(2S)-2-[1-(aminoiminomethyl)-4-piperidinyl]glycine]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 8
NTE modified (modifications unspecified)

| type | location | | description |
|---|---|---|---|
| stereo | Lys-1 | - | D |

SEQ3 1 Lys-Pro-Gly-Arg-Pro-Tyr-Ile-Leu
=== === === === === === === ===
HITS AT: 1-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF C72 H96 N16 O15 S

CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

PAGE 1-A



PAGE 2-A



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2005 ACS on STN
RN 579448-97-8 REGISTRY
CN 6-13-Neurotensin (cattle), 6-[N2-[[[3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5(or 6)-yl]amino]thioxomethyl]-D-lysine]-8-[(2S)-2-[1-(aminoiminomethyl)-4-piperidinyl]glycine]- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE
SQL 8
NTE modified (modifications unspecified)

| type | ------ location ------ | | description |
|---|---|---|---|
| stereo | Lys-1 | - | D |

SEQ3 1 Lys-Pro-Gly-Arg-Pro-Tyr-Ile-Leu
=== === === === === === === ===
HITS AT: 1-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF C72 H96 N16 O15 S
CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

PAGE 1-A






PAGE 2-A



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:51:51 ON 28 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 28 Mar 2005 VOL 142 ISS 14
FILE LAST UPDATED: 27 Mar 2005 (20050327/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que l8
L2 714 SEA FILE=REGISTRY ABB=ON PLU=ON .P.RPY.L/SQSP
L5 2127679 SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ES
L6 45 SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND L2
L7 7 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND SQL=8
L8 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

=> d .ca 18 102
2 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
ENTER ANSWER NUMBER OR RANGE (1):1-2

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:575856 HCAPLUS
DOCUMENT NUMBER: 141:12065
TITLE: Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer
AUTHOR(S): de Visser, M.; Janssen, P. J. J. M.; Srinivasan, A.; Reubi, J. C.; Waser, B.; Erion, J. L.; Schmidt, M. A.; Krenning, E. P.; de Jong, M.
CORPORATE SOURCE: Department of Nuclear Medicine, Erasmus MC, Rotterdam, 3015 GD, Neth.
SOURCE: European Journal of Nuclear Medicine and Molecular Imaging (2003), 30(8), 1134-1139
CODEN: EJNMA6; ISSN: 1619-7070
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 28 Jul 2003
AB Neurotensin (NT) receptors are overexpressed in exocrine pancreatic cancer and Ewing's sarcoma. The potential utility of native NT in cancer diagnosis and therapy is, however, limited by its rapid degradation in vivo. Therefore, NT analogs were synthesized with modified lysine and arginine derivs. to enhance stability and coupled either to DTPA, to enable high specific activity labeling with indium-111 for imaging, or to DOTA, to enable high specific activity labeling with β-emitting radionuclides, such as lutetium-177 and yttrium-90. Based on serum stability (4 h incubation at 37°C in human serum) and receptor binding affinity, the five most promising analogs were selected and further evaluated in in vitro internalization studies in human colorectal adenocarcinoma HT29 cells, which overexpress NT receptors. All five NT analogs bound with high affinity to NT receptors on human exocrine pancreatic tumor sections. The analogs could be labeled with 111In to a high specific activity. The 111In-labeled compds. were found to be very stable in serum. Incubation of HT29 cells with the 111In-labeled analogs at 37°C showed rapid receptor-mediated uptake and internalization. The most promising analog, peptide 2530 [DTPA-(Pip)Gly-Pro-(PipAm)Gly-Arg-Pro-Tyr-tBuGly-Leu-OH] was further tested in vivo in a biodistribution study using HT29 tumor-bearing nude mice. The results of this study showed low percentages of injected dose per g tissue of this 111In-labeled 2530 analog in receptor-neg. organs like blood, spleen, pancreas, liver, muscle and femur. Good uptake was found in the receptor-pos. HT29 tumor and high uptake was present in the kidneys. Co-injection of excess unlabeled NT significantly reduced tumor uptake, showing that tumor uptake is a receptor-mediated process. With their enhanced stability, maintained high receptor affinity and rapid receptor-mediated internalization, the 111In-labeled DTPA- and DOTA-conjugated NT analogs are excellent candidates for imaging and therapy of exocrine pancreatic cancer, peptide 2530 being the most promising analog.
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 8
IT 67-43-6DP, Dtpa, radiolabeled neurotensin analog conjugates 15750-15-9DP, Indium-111, neurotensin analogs labeled with, biological studies 39379-15-2DP, Neurotensin, radiolabeled analogs 60239-18-1DP,

Dota, radiolabeled neurotensin analog conjugates 328526-76-7P
**694452-76-1DP**, In(111)-labeled 697236-75-2P 697236-79-6P
697236-89-8P 697236-90-1P
RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stabilized 111In-labeled DTPA- and DOTA-conjugated neurotensin analogs for imaging and therapy of exocrine pancreatic cancer)
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:469885 HCAPLUS
DOCUMENT NUMBER: 139:185489
TITLE: Novel Bioactive and Stable Neurotensin Peptide Analogs Capable of Delivering Radiopharmaceuticals and Molecular Beacons to Tumors
AUTHOR(S): Achilefu, Samuel; Srinivasan, Ananthacari; Schmidt, Michelle A.; Jimenez, Hermo N.; Bugaj, Joseph E.; Erion, Jack L.
CORPORATE SOURCE: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA
SOURCE: Journal of Medicinal Chemistry (2003), 46(15), 3403-3411
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 20 Jun 2003
AB The prevalence of neurotensin receptor (NTR) in several human tumors makes it an attractive target for the delivery of cytotoxic drugs and imaging agents. Native neurotensin (NT) is a tridecapeptide that binds to NTR and induces tumor growth. Unfortunately, NT has a short plasma half-life, which hinders its use for in vivo biomedical applications. Numerous reports suggest that Arg(8)-Arg(9) and Tyr(11)-Ile(12) amide bonds are particularly susceptible to degradation by proteolytic enzymes. Predicated on this observation, we substituted Arg(8), Arg(9), and Ile(12) amino acids with the corresponding com. available mimics. These surrogate amino acids are amenable to standard Fmoc peptide synthesis strategy, and the resulting compds. are stable in biol. media for >4 h and bind to NTR with high affinity. Furthermore, conjugating DTPA to the new peptides and subsequent labeling with 111In-DTPA for nuclear imaging or fluorescein for optical imaging did not diminish the NTR binding affinities of the peptides. In vivo biodistribution of a representative 111In-DTPA-NT peptide analog in SCID mice bearing NTR-pos. human adenocarcinoma (HT29) xenograft shows that the compound was primarily retained in tumor tissue (2.2% ID/g) and the kidneys (4.8% ID/g) at 4 h postinjection. Coinjection of cold NT and the radiolabeled NT peptide analog inhibited the tumor but not the kidney uptake, demonstrating that retention of the radiolabeled compound in tumor tissue was mediated by NTR specific uptake while it accumulates in the kidneys by a nonspecific mechanism. These findings show that the new NT peptide analogs are robust and can deliver imaging agents to NTR-pos. tumors such as pancreatic cancer.
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 34
IT 202843-05-8P 578719-67-2P 578719-69-4P 578719-72-9P 578719-74-1P
578719-76-3P 578719-80-9P 578719-82-1P 578719-84-3P 578719-86-5P
578719-88-7P 578719-90-1P 578719-92-3P 578719-94-5P 578719-96-7P

578719-98-9P 578720-00-0P 578720-02-2P 578720-04-4P 578720-06-6P
578720-08-8P 578720-10-2P 578720-12-4P **579448-97-8P**
**579448-98-9P 579448-99-0P 579449-00-6P**
**579449-01-7P 579449-02-8P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel bioactive and stable neurotensin peptide analogs capable of delivering radiopharmaceuticals and mol. beacons to tumors)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>